Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2601-2605

  Van Besien, Herman ^a   Sassano, Antonella ^a   Altman, Jessica K ^a,b   Platanias, Leonidas C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Lymphoid leukemia; Myeloid leukemias and dysplasias; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; COMPACTIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; IMATINIB; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CHRONIC MYELOID LEUKEMIA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HUMAN; ISOPRENYLATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; GRAFT VS HOST DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84887227987     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.790022     Document Type: Review

References (41)

1. Gotto A M Jr, M oon J E. M anagement of cardiovascular risk: the importance of meeting lipid targets . Am J Cardiol 2012 ; 110(Suppl.) : 3A-14A .
2. Sassano A, Platanias LC . Statins in tumor suppression . Cancer Lett 2008 ; 260 : 11-19 .
3. Nielsen SF, Nordestgaard BG, Bojesen SE . Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802.
4. Goldstein JL, Brown MS . Regulation of the mevalonate pathway . Nature 1990 ; 343 : 425-430 .
5. Goedeke L, Fern á ndez-Hernando C . Regulation of cholesterol homeostasis . Cell Mol Life Sci 2012 ; 69 : 915-930 .
6. Porter KE, Turner NA . Statins and myocardial remodelling: cell and molecular pathways . Expert Rev Mol Med 2011; 13: e22.
7. Dimitroulakos J, Nohynek D, Backway KL, et al . Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach . Blood 1999; 93: 1308-1318.
8. Newman A, C lutterbuck R D, P owles R L, et a l. A comparison of the eff ect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors . Leuk Lymphoma 1997 ; 24 : 533-537 .
9. van der Weide K, d e Jonge-Peeters S, H uls G, et a l. T reatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients . Exp Hematol 2012 ; 40 : 177-186 .
10. Kornblau SM, Banker DE, Stirewalt D, et al . Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin-high-dose Ara-C: a phase 1 study . Blood 2007 ; 109 : 2999-3006 .
11. Li H Y, A ppelbaum F R, W illman C L, et a l. C holesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses . Blood 2003 ; 101 : 3628-3634 .
12. Xia Z, Tan MM, Wong WW, et al . Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells . Leukemia 2001 ; 15 : 1398-1407 .
13. van der Weide K, Korthuis PM, Kuipers F, et al . Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by diff erences in Ras-isoprenylation. Leukemia 2012; 26: 845-848.
14. van der Weide K, de Jonge-Peeters SD, Kuipers F, et al . Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic eff ect in a subset of primary CD34-acute myeloid leukemia samples . Clin Cancer Res 2009; 15: 3076-3083.
15. Stirewalt DL, Appelbaum FR, Willman CL, et al . Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin effi cacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 2003; 27: 133-145.
16. Sassano A, K atsoulidis E, A ntico G, et a l. S uppressive eff ects of statins on acute promyelocytic leukemia cells . Cancer Res 2007 ; 67 : 4524-4532 .
17. Sassano A, Lo Iacono M, Antico G, et al . Regulation of leukemic cell diff erentiation and retinoid-induced gene expression by statins . Mol Cancer Ther 2009 ; 8 : 615-625 .
18. Sassano A, Altman JK, Gordon LI, et al . Statin-dependent activation of protein kinase C in acute promyelocytic leukemia cells and induction of leukemic cell diff erentiation. Leuk Lymphoma 2012 ; 53 : 1779-1784 .
19. Kambhampati S, Li Y, Verma A, et al . Activation of protein kinase C delta by all-trans-retinoic acid . J Biol Chem 2003 ; 278 : 32544-32551 .
20. Williams AB, Li L, Nguyen B, et al . Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia . Blood 2012 ; 120 : 3069-3079 .
21. Minden MD, Dimitroulakos J, Nohynek D, et al . Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia . Leuk Lymphoma 2001; 40: 659-662.
22. Faderl S, O' B rien S, P ui C H, et a l. A dult acute lymphoblastic leukemia: concepts and strategies . Cancer 2010 ; 116 : 1165-1176 .
23. Stock W . Adolescents and young adults with acute lymphoblastic leukemia . Hematology Am Soc Hematol Educ Program 2010: 21-29.
24. Sheen C, V incent T, B arrett D, et a l. S tatins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis . Br J Haematol 2011 ; 155 : 403-407 .
25. Gribben JG, O' Brien S . Update on therapy of chronic lymphocytic leukemia . J Clin Oncol 2011 ; 29 : 544-550 .
26. Winiarska M, Bil J, Wilczek E, et al . Statins impair antitumor eff ects of rituximab by inducing conformational changes of CD20 . PLoS Med 2008 ; 5 : e64 .
27. Vitols S, A ngelin B, J uliusson G . S imvastatin impairs mitogeninduced proliferation of malignant B-lymphocytes from humans-in vitro and in vivo studies . Lipids 1997 ; 32 : 255-262 .
28. Juliusson G, V itols S . I mpaired low-density lipoprotein receptor activity in chronic B-lymphocytic leukaemia cells . Eur J Haematol 1988 ; 40 : 18-24 .
29. Chapman-Shimshoni D, Yuklea M, Radnay J, et al . Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9 . Exp Hematol 2003 ; 31 : 779-783 .
30. Shanafelt TD, Rabe KG, Kay NE, et al . Statin and non-steroidal anti-infl ammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia . Leuk Lymphoma 2010; 51: 1233-1240.
31. Friedman D R, M agura L A, W arren H A, et a l. S tatin use and need for therapy in chronic lymphocytic leukemia . Leuk Lymphoma 2010 ; 51 : 2295-2298 .
32. Cortes J, Hochhaus A, Hughes T, et al . Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia . J Clin Oncol 2011 ; 29 : 524-531 .
33. Yang YC, Huang WF, Chuan LM, et al . In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells . Chemotherapy 2008; 54: 438-446.
34. Chen R, Xiao W, Li D, et al . Combination of simvastatin and imatinib sensitizes the CD34-cells in K562 to cell death . Med Oncol 2011 ; 28 : 528-531 .
35. F, Myit S, et al . Statins as a newly recognized type of immunomodulator . Nat Med 2000 ; 6 : 1399-1402 .
36. Zeiser R, Maas K, Youssef S, et al . Regulation of diff erent infl ammatory diseases by impacting the mevalonate pathway . Immunology 2009 ; 127 : 18-25 .
37. Copelan E A. H ematopoietic stem-cell transplantation. N Engl J Med 2006 ; 354 : 1813-1826 .
38. Zeiser R, Youssef S, Baker J, et al . Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity . Blood 2007 ; 110 : 4588-4598 .
39. Hori A, Kanda Y, Goyama S, et al . A prospective trial to evaluate the safety and effi cacy of pravastatin for the treatment of refractory chronic graft-versus-host disease . Transplantation 2005; 79: 372-374.
40. Hamadani M, Awan FT, Devine SM . The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versushost disease in patients with acute leukemia undergoing allogeneic transplantation . Blood 2008 ; 111 : 3901-3902 .
41. Rotta M, Storer BE, Storb R, et al . Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation . Biol Blood Marrow Transplant 2010 ; 16 : 1463-1466 .